These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 17600392)
1. Didanosine enteric-coated capsule: current role in patients with HIV-1 infection. Moreno S; Hernández B; Dronda F Drugs; 2007; 67(10):1441-62. PubMed ID: 17600392 [TBL] [Abstract][Full Text] [Related]
2. Didanosine: an updated review of its use in HIV infection. Perry CM; Noble S Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M; Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623 [TBL] [Abstract][Full Text] [Related]
4. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630 [TBL] [Abstract][Full Text] [Related]
5. Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir. Gathe J; Badaro R; Grimwood A; Abrams L; Klesczewski K; Cross A; McLaren C J Acquir Immune Defic Syndr; 2002 Dec; 31(4):399-403. PubMed ID: 12447010 [TBL] [Abstract][Full Text] [Related]
6. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Perry CM; Balfour JA Drugs; 1996 Dec; 52(6):928-62. PubMed ID: 8957161 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M; J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678 [TBL] [Abstract][Full Text] [Related]
8. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231 [TBL] [Abstract][Full Text] [Related]
9. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
10. The power of simplicity. Lange J Int J STD AIDS; 2003 Oct; 14 Suppl 1():15-9. PubMed ID: 14617399 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. de Mendoza C; Ramos JT; Ciria L; Fortuny C; García FJ; de José MI; Asensi F; Soriano V HIV Clin Trials; 2002; 3(1):9-16. PubMed ID: 11819180 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. Saag MS; Cahn P; Raffi F; Wolff M; Pearce D; Molina JM; Powderly W; Shaw AL; Mondou E; Hinkle J; Borroto-Esoda K; Quinn JB; Barry DW; Rousseau F; JAMA; 2004 Jul; 292(2):180-9. PubMed ID: 15249567 [TBL] [Abstract][Full Text] [Related]
13. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. García F; Knobel H; Sambeat MA; Arrizabalaga J; Aranda M; Romeu J; Dalmau D; Segura F; Gomez-Sirvent JL; Ferrer E; Cruceta A; Gallart T; Pumarola T; Miró JM; Gatell JM; AIDS; 2000 Nov; 14(16):2485-94. PubMed ID: 11101059 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754 [TBL] [Abstract][Full Text] [Related]
15. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. Coakley EP; Gillis JM; Hammer SM AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277 [TBL] [Abstract][Full Text] [Related]
16. Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients. Palacios R; Aguilar I; Hidalgo A; Santos J Expert Rev Anti Infect Ther; 2006 Dec; 4(6):965-71. PubMed ID: 17181413 [TBL] [Abstract][Full Text] [Related]
17. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471 [TBL] [Abstract][Full Text] [Related]
18. Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. Borroto-Esoda K; Waters JM; Bae AS; Harris JL; Hinkle JE; Quinn JB; Rousseau FS AIDS Res Hum Retroviruses; 2007 Aug; 23(8):988-95. PubMed ID: 17725415 [TBL] [Abstract][Full Text] [Related]
19. Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects. Bongiovanni M; Tordato F Curr Med Chem; 2006; 13(23):2789-93. PubMed ID: 17073629 [TBL] [Abstract][Full Text] [Related]
20. Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy. Cahn P Expert Opin Investig Drugs; 2004 Jan; 13(1):55-68. PubMed ID: 14680453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]